42
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major updates every two years.

          Guideline highlights

          The 2019 Guidelines were extended with a new section focusing on drug–drug interactions and other prescribing issues in people living with HIV (PLWH). The recommendations for treatment‐naïve PLWH were updated with four preferred regimens favouring unboosted integrase inhibitors. A two‐drug regimen with dolutegravir and lamivudine, and a three‐drug regimen including doravirine were also added to the recommended initial regimens. Lower thresholds for hypertension were expanded to all PLWH and for cardiovascular disease prevention, the 10‐year predicted risk threshold for consideration of antiretroviral therapy (ART) modification was lowered from 20% to 10%. Frailty and obesity were added as new topics. It was specified to use urine albumin to creatinine ratio to screen for glomerular disease and urine protein to creatinine ratio for tubular diseases, and thresholds were streamlined with the Kidney Disease: Improving Global Outcomes (KDIGO) recommendations. Hepatitis C virus (HCV) treatment recommendations were split into preferred and alternative treatment options. The algorithm for management of recently acquired HCV infection was updated and includes recommendations for early chronic infection management. Treatment of resistant tuberculosis (TB) was streamlined with the World Health Organization (WHO) recommendations, and new tables on immune reconstitution inflammatory syndrome, on when to start ART in the presence of opportunistic infections and on TB drug dosing were included.

          Conclusions

          The EACS Guidelines underwent major revisions of all sections in 2019. They are available in four different formats including a new interactive web‐based version and are translated into Chinese, French, German, Japanese, Portuguese, Russian and Spanish.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana

          A preliminary safety signal for neural-tube defects was previously reported in association with dolutegravir exposure from the time of conception, which has affected choices of antiretroviral treatment (ART) for human immunodeficiency virus (HIV)-infected women of reproductive potential. The signal can now be evaluated with data from follow-up of additional pregnancies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

            HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons.

              The European AIDS Clinical Society (EACS) guidelines are intended for all clinicians involved in the care of HIV-positive persons, and are available in print, online, and as a free App for download for iPhone and Android.
                Bookmark

                Author and article information

                Contributors
                lene.ryom.nielsen@regionh.dk
                Journal
                HIV Med
                HIV Med
                10.1111/(ISSN)1468-1293
                HIV
                HIV Medicine
                John Wiley and Sons Inc. (Hoboken )
                1464-2662
                1468-1293
                03 September 2020
                November 2020
                : 21
                : 10 ( doiID: 10.1111/hiv.v21.10 )
                : 617-624
                Affiliations
                [ 1 ] CHIP Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases Section 2100 Center for Cardiac, Vascular, Pulmonary and Infectious Diseases Rigshospitalet University of Copenhagen Copenhagen Denmark
                [ 2 ] University College Dublin Centre for Experimental Pathogen Host Research Dublin Ireland
                [ 3 ] Infectious Diseases Unit La Paz Hospital Madrid Spain
                [ 4 ] Department of Infectious Diseases Inselspital Bern University Hospital University of Bern Bern Switzerland
                [ 5 ] Division of Infectious Diseases and Hospital Epidemiology Departments of Medicine and Clinical Research University Hospital of Basel and University of Basel Basel Switzerland
                [ 6 ] Department of Molecular and Clinical Pharmacology Institute of Translational Medicine University of Liverpool Liverpool UK
                [ 7 ] Department of Infectious Diseases St Louis and Lariboisière Hospitals APHP and University of Paris Paris France
                [ 8 ] Department of Surgical, Medical, Dental and Morphological Sciences University of Modena and Reggio Emilia Modena Italy
                [ 9 ] Imperial College London London UK
                [ 10 ] Department of Infectious Diseases/HIV Medicine Royal Free London NHS Trust Institute of Global Health University College London London UK
                [ 11 ] Division of Infectious Diseases San Raffaele Scientific Institute Milan Italy
                [ 12 ] Faculty of Medicine Medical University of Warsaw Warsaw Poland
                [ 13 ] HIV i‐Base and EATG London UK
                [ 14 ] Division of Infectious Diseases et Hospital Epidemiology University Hospital Basel and University of Basel Basel Switzerland
                Author notes
                [*] [* ] Correspondence: Dr Lene Ryom, CHIP, Center of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Department of Infectious Diseases, Section 2100, Center for Cardiac, Vascular, Pulmonary and Infectious Diseases, Blegdamsvej 9, DK‐2100 Copenhagen O, Denmark. Tel: + 45 35 45 57 65; fax: +45 35 45 57 57;

                e‐mail: lene.ryom.nielsen@ 123456regionh.dk

                [*]

                Members of the EACS Panels and Governing Board are listed in the Acknowledgements.

                Author information
                https://orcid.org/0000-0002-6436-6461
                https://orcid.org/0000-0002-5724-3914
                https://orcid.org/0000-0002-5847-8416
                https://orcid.org/0000-0003-1166-4462
                Article
                HIV12878
                10.1111/hiv.12878
                7754379
                32885559
                93cdcace-52f8-481c-bf69-ab74ec960c60
                © 2020 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 27 April 2020
                Page count
                Figures: 0, Tables: 3, Pages: 8, Words: 5566
                Categories
                European AIDS Clinical Society (EACS) guideline (HIV)
                European AIDS Clinical Society (EACS) guideline (HIV)
                Custom metadata
                2.0
                November 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.6 mode:remove_FC converted:22.12.2020

                Infectious disease & Microbiology
                antiretroviral treatment,comorbidities,drug–drug interactions,european aids clinical society (eacs) guidelines,hepatitis b virus,hepatitis c virus,hiv,opportunistic infections,prescribing in elderly patients

                Comments

                Comment on this article